Anna Gregson

Anna specialises in strategic patent management, including drafting and prosecuting applications, as well as coordinating worldwide patent families. As part of devising comprehensive, multi-layered protection around her clients’ innovations, she is an expert in patent landscape searching, monitoring of third-party patents and freedom-to-operate analysis. She is renowned for her ability to immerse herself in clients’ businesses, working with them to identify opportunities to add value through new intellectual property, and to provide creative solutions to strengthen their existing portfolios. With her keen commercial focus, Anna has been instrumental in developing IP portfolios that are the foundation of high-value spin-outs and university-industry partnerships.

With a formidable background in biochemistry and biotechnology, her technical expertise enables her to provide specialist IP advice in all areas of biotechnology, including technologies such as cell and gene therapies, vaccine technologies, antibodies, viruses and virus-like particles, siRNA technology, biomarkers and diagnostics, expression systems, recombinant protein technology and therapeutics. She also has significant expertise in the fields of plant biotechnology, biopesticides and plant variety rights.

Anna is equally happy working with experienced in-house professionals and start-ups and spin-outs with limited previous IP experience. She has significant expertise in working with university and public sector clients, and is adept at balancing technical excellence, budget control, transparency and predictability to develop bespoke IP strategies to match her clients’ needs.

Anna obtained a first class MA honours degree in natural sciences, specialising in pathology, from Cambridge University. She also holds a PhD in biochemistry from the University of Manchester for research into the control of angiogenesis in the eye.

Anna is a member of the Chartered Institute of Patent Attorneys (CIPA) and the European Patent Institute (EPI).